Active infection that requires systemic treatment
Active infection (any infection requiring systemic treatment)
Active infection requiring systemic treatment or any uncontrolled infection </=  days prior to enrollment
Has an active infection requiring systemic therapy within  days of registration (NOTE: except for uncomplicated urinary tract infection [UTI])
Active infection requiring treatment with systemic anti-infectives or major surgery in prior  weeks.
Active infection (any infection requiring systemic treatment)
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug
Has an active infection requiring systemic treatment
Active infection requiring systemic therapy; NOTE: when the infection is controlled, patients are permitted for this study
Active infection requiring IV anti-infective usage within the last  days prior to study treatment.
Active infection requiring systemic therapy at the time of study treatment initiation
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug.
Any uncontrolled infection or active infection requiring ongoing systemic treatment
Any active infection requiring systemic treatment
Patients with an active infection requiring treatment or having an unexplained febrile illness
Systemic infection requiring chronic maintenance or suppressive therapy
Participants with a history of an opportunistic fungal infection or active fungal infection requiring, or at high risk of requiring, prophylactic or treatment with fluconazole, voriconazole or posaconazole
Acute infection requiring systemic treatment
Ongoing infection requiring systemic treatment
Has history of/active pneumonitis that required/is requiring steroid treatment or had history of/active interstitial lung disease; has an active infection requiring systemic treatment
Active infection requiring treatment.
Has an active infection requiring intravenous systemic therapy or hospital admission
Has an active infection requiring intravenous systemic therapy or hospital admission
Has an active infection requiring systemic treatment
Active infection requiring treatment
Has an active infection requiring systemic therapy or hospital admission
Requiring active treatment for Toxoplasma gondii infection
Acute active infection requiring treatment should be under control
Patients with active infection requiring systemic antimicrobials
Active infection requiring treatment with systemic antibiotics or systemic anti-fungal agents
Subject has active infection requiring systemic therapy that has not completely resolved within  days prior to start of study treatment.
Patient has an active systemic infection requiring treatment or within  days before first dose of PRLX .
Serious, concomitant disorder, including active systemic infection requiring treatment, in the opinion of the investigator;
Active infection requiring treatment.
Evidence of active tuberculosis or recent clinically-significant infection requiring systemic therapy.
REGISTRATION TO TREATMENT (STEP ): Patient must not have an active infection requiring systemic therapy
REGISTRATION TO TREATMENT (STEP ): Patient must not have an active infection requiring systemic therapy
Acute infection requiring systemic treatment
Ongoing or active infection requiring systemic treatment (must be afebrile for >=  hours prior to study registration)
Has an active infection requiring systemic therapy with the exception of an uncomplicated urinary tract infection
Active infection requiring treatment or chronic infection requiring suppressive therapy
Active infection requiring systemic treatment within one week prior to first dose.
Active infection requiring treatment at the time of study treatment initiation
Requiring active treatment for Toxoplasma gondii
Systemic infection requiring chronic maintenance or suppressive therapy
Patients with active infection requiring systemic antimicrobials
Has an active infection requiring systemic treatment
Has an active infection requiring systemic treatment
Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
Active infection (any infection requiring treatment).
Ongoing or active infection requiring systemic treatment
Active infection requiring treatment
Active infection requiring treatment within two weeks prior to first dose.
Active infection (any infection requiring treatment).
Presence of an active systemic infection requiring treatment.
Active infection (any infection requiring systemic treatment)
Active infection requiring systemic treatment or any uncontrolled infections =<  days prior to enrollment
Active systemic hepatitis infection requiring treatment or other clinically active liver disease
Acute active infection requiring treatment.
Acute active infection requiring treatment.
Patient has an active systemic infection requiring treatment.
Patients with active infection requiring systemic treatment
Local or systemic infection
Active infection requiring IV anti-infective therapy
A serious, concomitant disorder, including active systemic infection requiring treatment
Current active infection requiring systemic treatment.
Has an active infection requiring systemic treatment
Active infection (any infection requiring treatment).
